WO2004028255A1 - Antimicrobial compositions - Google Patents
Antimicrobial compositions Download PDFInfo
- Publication number
- WO2004028255A1 WO2004028255A1 PCT/GB2003/004098 GB0304098W WO2004028255A1 WO 2004028255 A1 WO2004028255 A1 WO 2004028255A1 GB 0304098 W GB0304098 W GB 0304098W WO 2004028255 A1 WO2004028255 A1 WO 2004028255A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimicrobial
- composition according
- metal ion
- composition
- ion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
Definitions
- the present invention relates generally to antimicrobial agents and, in particular, to stabilized, metal-based antimicrobial agents suitable especially for topical applications in the prevention and treatment of infections and as a treatment for medical devices to make them infection resistant.
- Antimicrobial agents are chemical compounds and compositions that inhibit microbial growth or kill bacteria, fungi and other microorganisms.
- the antimicrobial activity of inorganic substances is generally related to the ions into which they dissociate.
- the antimicrobial activity of various metal ions for example, is often attributed to their affinity for protein material and the insolubility of the metal proteinate formed.
- Metal-containing salts are thus examples of inorganic substances that act as antimicrobial agents.
- Infection is a common complication associated with the use of medical devices.
- Various techniques have been described that incorporate potentially toxic metal ions in the form of metal salts into the materials which make up these medical, devices.
- U.S. Pat. No. 4,603,152 the disclosure of which is incorporated herein by reference, describes an antimicrobial composition useful in providing ; antimicrobial coatings on medical devices.
- particles of antimicrobial metal compounds are mixed in a polymer matrix and coated onto a . medical device to provide antimicrobial protection on that device.
- a major shortcoming of these techniques relates to the poor solubility and consequent slow surface diffusion of the metal salt in the hydrophic and lipophilic material matrix that makes up the medical devices. Indeed, because the antimicrobial metal salt must be on the surface of the medical device, the antimicrobial protection of the medical implant will last only as long as the metal- salt or compound is on the surface. Additionally, the metal ion is generally not photostable, and upon exposure to light is reduced to a metal, thereby losing antimicrobial efficiency.
- metal salt compounds are added to a separate polymer composition which is then used to coat the surface of the medical device, a problem arises because the coating of an implant with a separate polymer composition may change the dimensions of the medical device. Although this may not be important to medical devices such as wound dressings, a change in size of a medical implant such as a catheter may affect its usefulness.
- the disclosure of which is incorporated herein by reference, discloses the use of silver ion as an oligodynamic agent in a therapeutic or surface-treating composition or as an effective means for germicidally protecting an article or surface.
- the disclosed composition is comprised of a low concentration of a silver compound such as silver nitrate or silver oxide, a reducing agent such as starch or sugar, polyethylene glycol (PEG) and urea.
- a silver compound such as silver nitrate or silver oxide
- a reducing agent such as starch or sugar
- PEG polyethylene glycol
- This patent further teaches the addition of small amounts of sodium chloride or cupric chloride to the composition, to prevent discoloration even when the product is exposed to sterilization procedures and direct sunlight.
- metal ions such as copper and/or zinc is considered to stabilize the silver ion, making it more selective in its germicidal activity.
- metal ions such as copper and/or zinc
- the quantities of these metals in the composition should vary, he states that the ratio of copper and/or zinc to silver should be no greater than 2:1.
- compositions comprised of polyethylene glycol, a metal cation and an anion, is Kaplan, U.S. Pat. No.
- compositions comprised of cisplatin, PEG and a source of chloride ion, such as sodium chloride, for use in treating human neoplasms.
- Kaplan teaches that complexation of the cisplatin with PEG prevents crystallization of the cisplatin during storage and thereby maintains pharmaceutical activity.
- the compositions do not appear to be photostable, in that Kaplan explicitly teaches against exposing the composition to light.
- Capelli discloses antimicrobial metal-based compositions - which are said to be photostable, n ⁇ n-staining, and which are easily absorbed into lipophilic matrices - containing silver cations complexed by acyclic polyether polymers through the formation of a "host-guest relationship" where the acyclic polyether is the “host” and the silver cation is the “guest,” wherein stabilization of this "host- guest relationship" is accomplished through the use of excess halide anions.
- compositions are stated to be useful for topical treatment of infections caused by bacteria, fungus and viruses in humans and animals and for treating medical devices and adhesives to impart infection-resistance.
- Capelli's formulations are not suitable for incorporation into hydrophilic polymeric matrices such as hydrogels (e.g. sheet hydrogels, shaped hydrogels for example contact lenses, or hydrogel foam compositions), in that the resultant hydrogels do not have stability to gamma radiation and have to be carefully formulated to have light stability.
- the amount 55 is not have stability to gamma radiation and light.
- Hydrogel compositions e.g. for use in wound, burn and other dressings, are increasing in their use, due to their ability to provide moist healing environments.
- Such hydrogels may typically contain from about 2 to 80 or more % by weight of water.
- hydrogels which are resistant to microbial growth and are generally hostile to microorganisms such as bacteria, fungi and viruses.
- these dressings there is also a need for these dressings to be light and radiation stable, as radiation is typically applied in the polymerization procedure during manufacture. Hitherto, the requirement of radiation stability has limited the use of silver ions as an antimicrobial agent in hydrogel compositions.
- an antimicrobial agent suitable for incorporation into an aqueous composition such as, for example, a hydrogel, to impart to the composition an antimicrobial activity which is photostable and radiation stable, by using antimicrobial metal ions (e.g. silver ions) in the presence of a, molar excess (relative to the metal ions) of halide ions, for example chloride.
- antimicrobial metal ions e.g. silver ions
- halide ions for example chloride.
- a substantial molar excess, e.g. around 500 fold excess, of halide ions is used.
- compositions of the present invention leads to a decrease in the phoiostability and radiation stability.
- antimicrobial agents of the present invention are readily incorporated into hydrogel compositions such as, for example, sheet hydrogels, shaped hydrogels, amorphous hydrogels and foamed hydrogels
- the present invention provides photostable and radiation stable antimicrobial metal compositions useful in the treating infection and useful in preventing infection.
- the invention provides hydrogel compositions, for example sheet hydrogels, shaped hydrogels, amorphous hydrogels and foamed hydrogels, which are photostable and radiation stable possessing antimicrobial properties useful in the treating of infection and useful in preventing infection.
- the invention provides a manufacturing process whereby hydrogel compositions stable to light and radiation are made by photopolymerisation.
- the invention provides a manufacturing process whereby hydrogel compositions stable to light and radiation are made by radiation (for example electron beam and/or gamma) induced polymerization.
- radiation for example electron beam and/or gamma
- an antimicrobial agent wherein the antimicrobial activity is stable against both light and radiation, comprising an effective amount of antimicrobial metal (e.g. silver) ions and stabilizing halide ions, wherein the halide is present in an excess with respect to the amount of metal ions.
- antimicrobial metal e.g. silver
- the invention further provides compositions comprising the above antimicrobial agent for the treatment of infection in mammals or for providing antimicrobial protection to medical devices, wound dressings, sutures and other objects at risk of microbial infection (e.g. infection by bacteria, viruses or fungi).
- the compositions may, for example, be hydrogels or other pharmaceutical compositions including further pharmacologically acceptable carriers or diluents.
- compositions may be adhesive, e.g. adhesive to the skin (particularly, human skin).
- agent and compositions according to the present invention are distinguished from those described in US Patent No. 5,326,567, in that they have stability to gamma radiation. It is preferred that the agent and compositions according to the present invention are used in the effective absence of acyclic polyethers, to assist gamma stability. It is particularly preferred that the agent and compositions according to the present invention consist essentially of the metal and halide ions as the antimicrobially active component and stabilizer, with less than about 10%, particularly less than about 5%, by weight of any other antimicrobially active agent or stabilizer therefor.
- the antimicrobial agent according to the present invention is preferably present as solvated ions in intimate admixture in solution, particularly in aqueous solution.
- the solution is preferably entrained in a suitable reservoir or carrier such as the hydrogel compositions mentioned above.
- the present invention further provides a method of treating or preventing infection in a mammal, e.g. a human, in need thereof, comprising the step of administering to the mammal an antimicrobially effective amount of the agent or composition according to the present invention.
- the present, invention relates to antimicrobial metal-based agents and compositions which are photostable, radiation stable and easily incorporated into hydrogel matrices.
- the antimicrobial metal-based agents and compositions are preferably obtained by a method comprising forming a solution of the antimicrobial metal cation in the presence of excess halide anions and an amount of solvent.
- the solvent may be aqueous (water), organic or a mixture thereof, provided that the necessary ionic availability is achieved.
- solvent being water
- the "water activity" - as. defined by the equivalent relative humidity (ERH) of the halide solution into which the silver is dispersed - should preferably not exceed 75%.
- the preferred metal-based antimicrobial agents and compositions of the present invention have at least the following components:
- the molar halide excess should preferably be greater than 450, more preferably greater than 500.
- halide for example, chloride
- highly water soluble halide salts are required.
- the expression "highly water soluble” generally means that the salt in question forms at 20°C a saturated solution in water which has a concentration substantially greater than 0.1M, e.g. greater than about 1M or greater than about 2M.
- the use of salt solutions of monovalent metals, such as sodium chloride or potassium chloride, is not desirable as highly concentrated solutions are required to provide sufficient halide ion. These solutions are close to, or exceed saturation, and are of limited use - especially when the antimicrobial metal based composition is to incorporated into for example another matrix, for example a hydrogel.
- Preferred halide solutions are solvated forms of halide salts of multivalent cations such as, for example, calcium or magnesium or quaternary ammonium salts.
- Preferred salts are magnesium chloride and calcium chloride and the chlorides of quaternary ammonium salts.
- Preferred quaternary ammonium chloride salts are substituted vinyl compounds such as monomers or polymers. Examples include acryloyloxyethyltrimethyl ammonium chloride (DMAEA-Q, Kohjin) and acrylamidopropyltrimethyl ammonium chloride (Kohjin) and polymers and copolymers derived from them.
- the water activity of the solution into which the silver salt is dissolved must not exceed about 75% (ERH, as measured by a water activity meter, for example) and preferably is less than about 70%. It will be appreciated by those skilled in the art that the terms osmolality, isotonicity, hyper-tonicity and hypo-tonicity are alternative descriptions of the water activity in the solution or material and hence are to be considered equivalent.
- the silver ions are preferably the solvated ions derived from a soluble silver salt, for example silver nitrate, silver acetate, silver sulphate or silver lactate, preferably silver nitrate.
- the silver ions are present in the stable salt solution at antimicrobially effective concentrations, according to the manner in which the material/solution is to be applied to the medical device or topically to the body.
- the effective amount is typically from about 0.01 to about 0.5% by weight of the solution.
- the stabilized silver salt solution (herein: SSSS) may be diluted with water, or aqueous liquids or solutions or other compounds soluble in the SSSS (such that the water activity does not exceed about 75% ERH).
- SSSS aqueous liquids or solutions or other compounds soluble in the SSSS (such that the water activity does not exceed about 75% ERH).
- Polyhydric alcohols for example glycerol or sorbitol, may be used as diluents.
- Polyethylene glycols have been found to destabilize the SSSS, and should preferably not be used.
- the SSSS may be readily incorporated in to many different types of hydrogel (also including hydrocolloids) and impart excellent antimicrobial properties (as 'determined by USP 25/2000 Antimicrobial Preservative Effectiveness).
- the hydrogels are polymerized monomers, which may be homopolymers or copolymers and may, for example, be based on ionic (cationic, anionic, amphoteric or zwitterionic) monomers and comonomers, non-ionic monomers and comonomers, or any combination or mixture thereof.
- the hydrogels are preferably cross-linked. Examples of relevant chemistries and hydrogels can be found in published PCT patent applications nos. PCT/GB99/02505 and PCT/G BOO/00302, the contents of which are incorporated herein by reference.
- anionic monomers include the sodium or potassium salt of acrylic acid or methacrylic acid, the sodium or potassium salt of 3-sulphopropyl acrylate (SPA) or the corresponding methacrylate, and the sodium or potassium salt of 2- acrylamido-2-methylpropane sulphonic acid (NaAMPS), or any combination or mixture thereof, including mixtures of any two or all three.
- SPA sodium or potassium salt of 3-sulphopropyl acrylate
- NaAMPS 2- acrylamido-2-methylpropane sulphonic acid
- a cationic monomer is preferably either a quaternary ammonium salt derivative of acrylic acid/methacrylic acid or a quaternary ammonium salt derivative of an N- substituted acrylamide or combinations of both.
- Preferred examples include acryloyloxyethyltrimethyl ammonium chloride (DMAEA-Q, Kohjin), acryloyloxyethyltrimethyl ammonium methyl sulphate (Aldrich), acrylamidopropyltrimethyl ammonium chloride (Kohjin).
- Copolymers comprising both anionic and cationic monomers may also be useful.
- the molar ratios of cationic and anionic monomers are unity, the resulting hydrogel may exhibit amphoteric behaviour (the hydrogel swells more in salt solution than in pure water).
- a non-ionic monomer may, for example, be selected from acryloyl-morpholine (ACMO), e.g. N-acryloylmorpholine, 1-acryloylmorpholine, or 2-acryloylmorpholine; an acrylamide; an N-substituted acrylamide; an acrylic/methacryJic acid; a vinyl lactam; and N-vinylpyrrolidone.
- ACMO acryloyl-morpholine
- the hydrogel composition is preferably formed in generally conventional manner, by polymerising a mix (the "pre-.mix”).
- the total amount of monomer .or co- monomer present in the pre- polymerisation mix is about 1- 60%, preferably about 10-45%, preferably about 20-45%, by weight of the total composition, such that the molar ratio of anionic to cationic monomer is preferably from about 0.8 to about 1.2, preferably about 0.9 to about 1.1 , preferably about 0.95,to about 1.05 and more preferably about 1.
- the balance of the composition preferably comprises the stabilised silver salt solution, water (preferably about 2 to about 80%, preferably about 5 to about 60%, by weight of the total mix), a polyhydric alcohol (0 to about 50%, preferably about 10 to about 40%, by weight, where the polyhydric alcohol is preferably glycerol (Aldrich)), a cross-linking agent (preferably about 0.04% to about 5 %, preferably about 0.06 to about 0.3%, by weight, where the preferred cross-linking agent is polyethylene glycol di-acrylate (Aldrich)), optionally a photo-initiator (Darocure 1173 or Irgacure 184 or any combination thereof; preferably 0.001% to about 0.1% by weight), and optional additional ingredients, such as, for example, medicaments, adhesion promoters or surfactants (e.g. 0% to about 10% by weight total of such optional additional ingredients).
- water preferably about 2 to about 80%, preferably about 5 to about 60%, by weight of the total mix
- the hydrogel can be made in generally conventional manner by casting the pre- polymerisation mix on to a suitable substrate (for example, a sheet, film, non- woven sheet, film or tube, which may be formed from any suitable material, for example a synthetic or natural polymer or a ceramic material), and curing the mix. Curing may, for example be effected with the aid of light (preferably UV).
- the pre- polymerisation mix may alternatively be cured with the aid of an electron beam or ionising radiation, for example gamma. In these cases the photo-initiator is not required.
- a thermal initiator may be substituted for the photo-initiator and the pre- mix alternatively cured by means of heat.
- a continuous film may be made by coating the mix onto a substrate (which is preferably siliconised for easy release), which may be a polymer such as polyester, polyethylene, polypropylene, polyurethane, or paper, or a web, net, foam or a non-woven material, e.g. made from natural and/or synthetic materials.
- a substrate which is preferably siliconised for easy release
- the coated substrate is then cured, e.g. by being passed under a UV light.
- a siliconised cover is preferably placed on top of the exposed surface of the hydrogel.
- the thickness of the hydrogel film can typically be from about 0.05mm to about 3mm.
- a foamed hydrogel of the present invention comprises a cellular structure within the bulk of the hydrogel material, preferably extending also to the surface of the material.
- a hydrogel can suitably be made by mechanically agitating the premix and then coating the agitated (aerated) pre-mix onto a substrate (web) as for the film.
- the foam so formed can be porous throughout its thickness or can be coated such that a composite structure of film supporting a foam can be made.
- the thickness of the foam or film foam structure can typically be from about 0.1mm to about 3mm.
- Pre-made hydrophilic polymers/copolymers and mixtures thereof, natural and/or synthetic may be added to the premix in an amount up to about 10% by weight.
- Pre-made hydrophilic polymers, copolymers and mixtures thereof may also be used in place of the monomers and crosslinked by means of light, ionising radiation or electron beam.
- a stabilised silver salt solution was made by first making an aqueous solution of the stabilising salt and adding a 1 M aqueous silver nitrate solution according .the amounts specified in the following pre-polymerisation formulations.
- the pre- polymerisation formulations were assembled as described in, for example, PCT patent applications nos. PCT/GB99/02505 and PCT/GBOO/00302.
- PI/XL refers to the total amount of photoinitiator (Darocur1173) and crosslinker (polyethylene glycol di-acrylate (IRR 280, UCB)) used per 100g of formulation.
- the ratio of photoinitiator to crosslinker is typically 4/20.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Inorganic Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003269177A AU2003269177A1 (en) | 2002-09-25 | 2003-09-25 | Antimicrobial compositions |
EP03750955A EP1542534A1 (en) | 2002-09-25 | 2003-09-25 | Antimicrobial compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0222259A GB0222259D0 (en) | 2002-09-25 | 2002-09-25 | Antimicrobial compositions |
GB0222259.4 | 2002-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004028255A1 true WO2004028255A1 (en) | 2004-04-08 |
Family
ID=9944748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/004098 WO2004028255A1 (en) | 2002-09-25 | 2003-09-25 | Antimicrobial compositions |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1542534A1 (en) |
AU (1) | AU2003269177A1 (en) |
GB (1) | GB0222259D0 (en) |
WO (1) | WO2004028255A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1809264A2 (en) * | 2004-09-20 | 2007-07-25 | Acrymed, Inc. | Antimicrobial amorphous compositions |
US7939578B2 (en) | 2007-02-23 | 2011-05-10 | 3M Innovative Properties Company | Polymeric fibers and methods of making |
US8203029B2 (en) | 1997-11-14 | 2012-06-19 | Kimberly-Clark Worldwide, Inc. | Silver-containing compositions, devices and methods for making |
US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
US8361553B2 (en) | 2004-07-30 | 2013-01-29 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for metal nanoparticle treated surfaces |
US8414547B2 (en) | 2004-04-29 | 2013-04-09 | C. R. Bard, Inc. | Modulating agents for antimicrobial coatings |
US8486426B2 (en) | 2002-07-29 | 2013-07-16 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for treatment of dermal conditions |
US8679523B2 (en) | 1999-12-30 | 2014-03-25 | Kimberly-Clark Worldwide, Inc. | Oxygen-delivery closed cell foam matrix for wound treatment |
US8900624B2 (en) | 2004-07-30 | 2014-12-02 | Kimberly-Clark Worldwide, Inc. | Antimicrobial silver compositions |
US9763453B2 (en) | 2004-04-29 | 2017-09-19 | Bacterin International, Inc. | Antimicrobial coating for inhibition of bacterial adhesion and biofilm formation |
US10251392B2 (en) | 2004-07-30 | 2019-04-09 | Avent, Inc. | Antimicrobial devices and compositions |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992018098A1 (en) * | 1991-04-10 | 1992-10-29 | Capelli Christopher C | Antimicrobial compositions useful for medical applications |
WO1996001119A1 (en) * | 1994-07-01 | 1996-01-18 | Capelli Christopher C | Antimicrobial compositions useful for medical applications |
WO1997002038A1 (en) * | 1995-06-30 | 1997-01-23 | Capelli Christopher C | Silver-based pharmaceutical compositions |
EP0911297A1 (en) * | 1997-10-24 | 1999-04-28 | Joseph A. King | Water treatment composition and method of making |
WO2002043743A1 (en) * | 2000-11-29 | 2002-06-06 | Bristol-Myers Squibb Company | Light stabilized antimicrobial materials |
WO2003051408A1 (en) * | 2001-12-19 | 2003-06-26 | First Water Limited | Hydrogel compositions comprising an acryloyl morpholine polymer |
-
2002
- 2002-09-25 GB GB0222259A patent/GB0222259D0/en not_active Ceased
-
2003
- 2003-09-25 WO PCT/GB2003/004098 patent/WO2004028255A1/en not_active Application Discontinuation
- 2003-09-25 AU AU2003269177A patent/AU2003269177A1/en not_active Abandoned
- 2003-09-25 EP EP03750955A patent/EP1542534A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992018098A1 (en) * | 1991-04-10 | 1992-10-29 | Capelli Christopher C | Antimicrobial compositions useful for medical applications |
WO1996001119A1 (en) * | 1994-07-01 | 1996-01-18 | Capelli Christopher C | Antimicrobial compositions useful for medical applications |
WO1997002038A1 (en) * | 1995-06-30 | 1997-01-23 | Capelli Christopher C | Silver-based pharmaceutical compositions |
EP0911297A1 (en) * | 1997-10-24 | 1999-04-28 | Joseph A. King | Water treatment composition and method of making |
WO2002043743A1 (en) * | 2000-11-29 | 2002-06-06 | Bristol-Myers Squibb Company | Light stabilized antimicrobial materials |
WO2003051408A1 (en) * | 2001-12-19 | 2003-06-26 | First Water Limited | Hydrogel compositions comprising an acryloyl morpholine polymer |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8203029B2 (en) | 1997-11-14 | 2012-06-19 | Kimberly-Clark Worldwide, Inc. | Silver-containing compositions, devices and methods for making |
US9687503B2 (en) | 1999-12-30 | 2017-06-27 | Avent, Inc. | Devices for delivering oxygen to the wounds |
US8679523B2 (en) | 1999-12-30 | 2014-03-25 | Kimberly-Clark Worldwide, Inc. | Oxygen-delivery closed cell foam matrix for wound treatment |
US8486426B2 (en) | 2002-07-29 | 2013-07-16 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for treatment of dermal conditions |
US8414547B2 (en) | 2004-04-29 | 2013-04-09 | C. R. Bard, Inc. | Modulating agents for antimicrobial coatings |
US9763453B2 (en) | 2004-04-29 | 2017-09-19 | Bacterin International, Inc. | Antimicrobial coating for inhibition of bacterial adhesion and biofilm formation |
US8361553B2 (en) | 2004-07-30 | 2013-01-29 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for metal nanoparticle treated surfaces |
US8900624B2 (en) | 2004-07-30 | 2014-12-02 | Kimberly-Clark Worldwide, Inc. | Antimicrobial silver compositions |
US9888691B2 (en) | 2004-07-30 | 2018-02-13 | Avent, Inc. | Antimicrobial silver compositions |
US10251392B2 (en) | 2004-07-30 | 2019-04-09 | Avent, Inc. | Antimicrobial devices and compositions |
EP1809264A2 (en) * | 2004-09-20 | 2007-07-25 | Acrymed, Inc. | Antimicrobial amorphous compositions |
US9289378B2 (en) | 2004-09-20 | 2016-03-22 | Avent, Inc. | Antimicrobial amorphous compositions |
EP1809264A4 (en) * | 2004-09-20 | 2008-11-19 | Acrymed Inc | Antimicrobial amorphous compositions |
US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
US7939578B2 (en) | 2007-02-23 | 2011-05-10 | 3M Innovative Properties Company | Polymeric fibers and methods of making |
Also Published As
Publication number | Publication date |
---|---|
EP1542534A1 (en) | 2005-06-22 |
AU2003269177A1 (en) | 2004-04-19 |
GB0222259D0 (en) | 2002-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2343675T3 (en) | ANTIMICROBIAL MATERIALS STABILIZED AGAINST LIGHT. | |
US5744151A (en) | Silver-based pharmaceutical compositions | |
JP4416844B2 (en) | Cross-linked polyvinyl pyrrolidone-iodine composite and method for producing the same | |
KR100411178B1 (en) | Novel antibacterial agents, and antibacterial and deordorizing solution comprising them | |
JPH0257262A (en) | Medical material | |
JPH07503978A (en) | Skin-adhesive hydrogel, its preparation and use | |
WO2004028255A1 (en) | Antimicrobial compositions | |
US5242985A (en) | Aqueous stable complex of a strongly swellable, moderately crosslinked polyvinylpyrrolidone and iodine | |
US20100028290A1 (en) | Disinfectant | |
CN109620842B (en) | Cross-linked polyvinylpyrrolidone and iodine complex, and preparation method and application thereof | |
JPS63109865A (en) | Pullulan film preparation containing drug as effective component | |
AU750719B2 (en) | Silver-based pharmaceutical compositions | |
Pu | A dressing solution for burn wounds: antibacterial and low-adherent wound dressings | |
CZ2006197A3 (en) | Disinfecting agent | |
JP2001516722A (en) | Burn treatment composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003750955 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003750955 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003750955 Country of ref document: EP |